Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01738906
Other study ID # P9532
Secondary ID
Status Completed
Phase N/A
First received November 28, 2012
Last updated January 2, 2013
Start date October 2012
Est. completion date December 2012

Study information

Verified date January 2013
Source TNO
Contact n/a
Is FDA regulated No
Health authority Netherlands: Medical Ethics Review Committee (METC)Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

Rationale

It has been shown in several studies that alcohol increases subsequent food intake. However, moderate alcohol consumption has no clear effects on hunger and satiety hormones. In the Western world, where palatable food is highly available, food reward may play an important role in food intake. Alcohol consumption is known to stimulate neurotransmitters important for food reward and may therefore stimulate the reward response on a subsequent meal. This may lead to higher food consumption than when no alcohol is consumed. It is hypothesized that the reward response of food or beverages can already be generated when food or beverages are sensed in the mouth, because oral nutrient sensing is known to induce a satiety response (i.e. the cephalic phase response). Moreover, taste buds directly signal brain areas closely connected to the reward areas in the brain.

Primary objective

- To determine whether moderate alcohol consumption influences subsequent food reward, as measured by questionnaires on food 'wanting' and food 'liking', and salivary and blood parameters related to reward.

Secondary objectives

- To determine whether food reward is different when food is consumed than when food is sensed in the mouth, as measured by questionnaires on food 'wanting' and food 'liking', and salivary and blood parameters related to food reward.

- To determine whether moderate alcohol consumption influences subsequent food reward differently when food is consumed than when food is sensed in the mouth, as measured by questionnaires on food 'wanting' and food 'liking', and salivary and blood parameters related to food reward.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 25 Years to 50 Years
Eligibility Inclusion Criteria:

- Caucasian men;

- Age 25-50 years on the day of the screening;

- Body Mass Index (BMI) of 20-25 kg/m2;

- Body weight of 60-100 kg;

- Able to read, write and fully understand the Dutch language, and

- Able to participate int he sudy, willing to give written informed consent and to comply with the study procedures and restrictions.

Exclusion Criteria:

- Above average score (>2.26) on the restrained scale of the Dutch Eating Behaviour Questionnaire;

- Alcohol consumption <6 and >20 standard glasses/week;

- Not having regular and normal Dutch eating habits;

- Not having a normal day/night rhythm;

- Smoking, or stopped with smoking <3 months prior to start of the study;

- Using drugs, or stopped using drugs <3 months prior to start of the study;

- Having a (family) history of alcohol or drug related problems;

- Reported slimming or being on a medically described diet;

- Having a vegan, vegetarian or macrobiotic lifestyle;

- Loss of blood outside the limits of Sanquin within 3 months prior to screening;

- Participation in a clinical trial within 3 months prior to the start of this study or more than 4 times a year;

- Having a food allergy, sensitivity or disliking one of the foods used in the study;

- Reported unexplained weight loss or gain of >4 kg in the month prior to the screening;

- Inappropriate veins for cannula insertion;

- Not having a general practitioner or health insurance;

- Having a history of medical or surgical events or disease that may significantly affect the study outcome, particularly physiological disorders, metabolic or endocrine disease and gastrointestinal disorders; and/or

- Any condition which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Other:
Orange juice

maltodextrin

Vodka

butter cake MSF
chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
butter cake consumption
chewing for 6 min on 40 gram cake and then swallow it.

Locations

Country Name City State
Netherlands Centre for Human Drug Research (CHDR) Leiden Zuid-Holland

Sponsors (3)

Lead Sponsor Collaborator
Henk FJ Hendriks Foundation for Alcohol Research (SAR), The Netherlands, Ministry of Economic Affairs, The Netherlands

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Explicit food 'wanting' Questionnaire measuring food 'wanting' explicitly with the question: "How much do you want to eat at this moment?" This is scored on a visual analogue scale ranging from 0-100. up to 75 minutes No
Primary Implicit food 'wanting' for different food categories Computer task measuring food 'wanting' implicitly for different food categories. This is a forced choice task in which subjects have to choose as quick and precise the food product they want to eat most at that moment. up to 30 minutes No
Primary explicit food 'wanting' for different food categories Questionnaire measuring food wanting explicitly for different food categories on a visual analogue scale (ranging 0-100). up to 30 minutes No
Primary explicit food 'liking' for different food categories Questionnaire measuring food 'liking' for different food categories on a visual analogue scale (ranging 0-100). up to 30 minutes No
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2